TARS | Ticker Profile - Titan Protect

TARS

Tarsus Pharmaceuticals, Inc.

Healthcare · Biotechnology · NMS

$59.28

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.6B

Total market value of the company

Trailing P/E

N/A

Forward P/E

20.95

Based on estimated future earnings — lower means cheaper

Rev Growth

+106.9%

Year-over-year revenue change

Profit Margin

-9.0%

How much profit the company keeps from each dollar of revenue

ROE

-14.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$95.00

+60% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 9 analysts covering this stock

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

https://tarsusrx.com

Country: United States Employees: 370 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.789

Good returns relative to risk taken

Kelly Fraction

0.0616

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.821

Acceptable balance between returns and drawdown risk

Annual Return

31.2%

Historical annualised return based on price data

Max Drawdown

-38.0%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.53

Less volatile than the market — more defensive

52W High

$85.25

30% below the year high

52W Low

$38.51

54% above the year low

Avg Volume

589,475

Average daily shares traded — higher means easier to buy and sell

Short Ratio

6.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

11.8%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.11

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

25.41

Heavy leverage — higher financial risk if revenues decline

Current Ratio

3.74

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

3.53

Like current ratio but excludes inventory — stricter test

Gross Margin

80.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-3.8%

Profit from core operations before interest and tax

Free Cash Flow

$-21,268,124

Negative — the business is spending more than it generates

Revenue (TTM)

$535M

Total revenue over the last 12 months

Net Income

$-48,265,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$100.00

Target Median

$95.00

Target Low

$88.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go